Table 3. Atazanavir (ATV) plasma trough concentrations measured in patients that did or did not experienced drug-related adverse events.
| Adverse event | n | Overall patients | n | ATV/r 300/100 | n | ATV 400 |
|---|---|---|---|---|---|---|
| Hyperbilirubinemia | ||||||
| - Grade 0 | 86 | 271 (77–555) | 52 | 347 (121–785) | 34 | 141 (56–293) |
| - Grade 1 | 45 | 548 (206–902) | 30 | 634 (355–962) | 15 | 194 (106–358) |
| - Grade 2 | 54 | 793 (440–1164)* | 40 | 909 (586–1264)** | 14 | 466 (260–804)** |
| - Grade 3 | 41 | 768 (494–1527)* | 31 | 825 (531–1368)** | 10 | 540 (394–1979)* |
| - Grade 4 | 7 | 1491 (1122–1798)* | 6 | 1363 (1066–1693)** | 1 | 1836 |
| Dyslipidemia | 55 | 582 (266–1148)* | 44 | 746 (305–1313)** | 11 | 250 (106–486) |
| Nephrolitiasis | 11 | 1098 (631–1238)* | 9 | 1098 (652–1285)** | 2 | 742 (293–1191) |
| Controls^ | 66 | 218 (77–541) | 39 | 343 (125–810) | 27 | 141 (50–259) |
Data were stratified also according to ritonavir use.
^patients that did not develop ATV-related adverse events;
*p<0.01 and
**p<0.05 vs. controls